The First Affiliated Hospital of Sun Yat sen University No.183 Huangpu East Road, Huangpu District, Guangzhou City, Guangdong Province, China.
The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital) No. 36 Mingxin Road, Liwan District, Guangzhou City, Guangdong Province, China.
Recent Pat Anticancer Drug Discov. 2021;16(1):101-107. doi: 10.2174/1574892815999201231215311.
Cholangiocarcinoma is the second-largest liver cancer, and develops from the biliary epithelium, where it discretely progresses. Unfortunately, many patients miss the opportunity of performing surgery when diagnosed with cholangiocarcinoma, and due to its chemotherapeutic insensitivity, its control has always been considered difficult.
Here, we present a case of stage 4 cholangiocarcinoma being controlled by the combination of chemotherapy with PD-1 and VEGF/VEGFR2 inhibitors.
The patient is a 58-year-old male who was diagnosed with a progressed cholangiocarcinoma 2 years ago. From the beginning, metastases were discovered in multiple places, and the patient was unsuccessfully treated with 3 chemotherapy regimens. Therefore, a new therapeutic method was considered, and that involved the testing of a new combination of chemotherapy with PD-1 and VEGF/VEGFR2 inhibitors.
After 6 courses of treatment with this combination, the patient's lesions became smaller and stable.
Our case highlights the possibility of combining chemotherapy with PD-1 and VEGF/ VEGFR2 inhibitors for the treatment of cholangiocarcinoma patients. This combination may herald new hope for patients who run out of regimens.
胆管癌是第二大肝癌，起源于胆管上皮，呈局灶性进展。不幸的是，许多胆管癌患者在诊断时已经错过了手术机会，并且由于其对化疗不敏感，其控制一直被认为是困难的。
本研究报道了一例采用化疗联合 PD-1 和 VEGF/VEGFR2 抑制剂治疗的 4 期胆管癌病例。
患者为 58 岁男性，2 年前被诊断为进展期胆管癌。从一开始，就发现多处转移，患者接受了 3 种化疗方案的治疗均未成功。因此，考虑采用一种新的治疗方法，即测试化疗联合 PD-1 和 VEGF/VEGFR2 抑制剂的新组合。
该患者接受了 6 个疗程的联合治疗后，其病灶缩小且稳定。
本病例提示，化疗联合 PD-1 和 VEGF/VEGFR2 抑制剂治疗胆管癌患者是可能的。对于无药可用的患者，这种联合治疗可能带来新的希望。
